Core Insights - Zoetis Inc. is a leading global animal health company that develops, manufactures, and markets veterinary vaccines and medicines, serving veterinarians, livestock producers, and pet owners [1] - KeyBanc initiated coverage of Zoetis with a "Sector Weight" rating, indicating expectations for the company's performance to align with the broader sector [2][5] - The stock price of Zoetis has fluctuated significantly, with a year high of $181.85 and a low of $115.25, reflecting its substantial market presence with a market capitalization of approximately $51.07 billion [4][5] Company Participation - Zoetis is scheduled to participate in the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025, with CEO Kristin Peck and CFO Wetteny Joseph representing the company [3][5] - The conference will provide insights into the company's strategies and performance, with a live audio webcast available for investors [3] Stock Performance - The stock price of Zoetis was $115.89 when KeyBanc initiated coverage, reflecting a decrease of 1.02% or $1.19 on that day [2] - During the trading day, the stock price fluctuated between $115.80 and $118.43, with a trading volume of 3,260,584 shares [4]

Company Overview - Zoetis Inc. is a leading global animal health company focused on veterinary vaccines and medicines, operating in over 100 countries and serving veterinarians, livestock producers, and pet owners [1] Recent Performance - Over the past month, Zoetis's stock has increased by 0.013%, indicating a steady upward trend, while experiencing a decline of 3.23% in the last 10 days, which may present a strategic entry point for investors [2][6] Growth Potential - The company has a projected stock price increase of 21.28%, suggesting significant upside potential for investors, supported by its strong market position and fundamentals [3][6] Financial Health - Zoetis has a Piotroski Score of 8, reflecting strong financial stability and operational efficiency, which is crucial for long-term growth and investor confidence [4][6] Analyst Outlook - Analysts have set a target price of $181.67 for Zoetis, indicating optimism about the stock's future performance and aligning with the company's growth potential [5]